CTNM

Contineum Therapeutics Inc

Jun 02 • 04:00PM ET

12.38

-0.71 -5.42 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: INCY KYMR NUVL BMRN RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: VTI VXF IBB SCHA IWC DFAS AVSC DFMC SCHB DFAU

Index	-	P/E	-	EPS (ttm)	-1.95	Insider Own	21.82%	Shs Outstand	32.72M	Perf Week	-9.64%
Market Cap	462.85M	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-0.68%	Shs Float	29.23M	Perf Month	-6.21%
Enterprise Value	223.47M	PEG	-	EPS next Q	-0.45	Inst Own	73.61%	Short Float	4.85%	Perf Quarter	-12.20%
Income	-58.44M	P/S	-	EPS this Y	24.09%	Inst Trans	2.30%	Short Ratio	5.23	Perf Half Y	11.83%
Sales	0.00M	P/B	1.85	EPS next Y	-10.15%	ROA	-25.43%	Short Interest	1.42M	Perf YTD	8.31%
Book/sh	6.69	P/C	1.88	EPS next 5Y	4.19%	ROE	-26.88%	52W High	16.33 -24.19%	Perf Year	179.46%
Cash/sh	6.59	P/FCF	-	EPS past 3/5Y	-30.91% -	ROIC	-22.95%	52W Low	3.57 246.78%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.47% 6.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-1.14%	Oper. Margin	-	ATR (14)	0.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	38.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	40.01	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	38.00	EPS Q/Q	37.36%	SMA20	-9.81%	Beta	0.91	Target Price	22.33
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-6.86%	Rel Volume	0.89	Prev Close	13.09
Employees	51	LT Debt/Eq	0.02	Earnings	May 05 AMC	SMA200	0.15%	Avg Volume	270.90K	Price	12.38
IPO	Apr 05, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.68% -	Trades		Volume	242,288	Change	-5.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$14
Nov-13-25	Initiated	Leerink Partners	Outperform	$22
Sep-25-25	Initiated	Leerink Partners	Outperform	$20
Jun-20-25	Initiated	William Blair	Outperform
Oct-22-24	Initiated	Robert W. Baird	Outperform	$32
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

Jun-01-26 04:05PM	Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference (Business Wire) -5.42%
May-15-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.27%
May-12-26 04:05PM	Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference (Business Wire)
May-11-26 04:05PM	Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference (Business Wire) -6.06%
May-05-26 04:05PM	Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
04:05PM	Loading…
May-01-26 04:05PM	Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.20%
Apr-30-26 04:05PM	Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain (Business Wire) +6.48%
Mar-13-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.20%
Mar-05-26 04:05PM	Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire) -7.07%
Mar-03-26 04:05PM	Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference (Business Wire) -8.08% +5.39%
Mar-02-26 08:25AM	Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus (Zacks)
Feb-18-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.12%
Feb-04-26 09:40AM	Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-28-26 04:05PM	Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-31-25 12:00PM	Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Loading…
09:55AM	Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? (Zacks)
Dec-11-25 10:24PM	Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering (Business Wire) -11.02%
04:05PM	Contineum Therapeutics Announces Proposed $75.0 Million Public Offering (Business Wire)
Nov-24-25 04:05PM	Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference (Business Wire) -5.34%
Nov-21-25 01:44AM	A brain biotechs top drug fails against MS (BioPharma Dive) -10.43%
Nov-20-25 04:05PM	Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) (Business Wire)
Oct-30-25 04:05PM	Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
Sep-18-25 08:05AM	Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
Aug-28-25 04:05PM	Contineum Therapeutics to Present at September Investor Conferences (Business Wire)
Aug-08-25 09:55AM	Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet (Zacks)
Aug-05-25 04:05PM	Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones (Business Wire) +5.50%
Jun-25-25 08:15AM	Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
May-15-25 04:05PM	Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference (Business Wire) -10.91%
May-14-25 04:05PM	Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones (Business Wire)
Apr-28-25 04:05PM	Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development (Business Wire)
04:05PM	Loading…
Mar-17-25 04:05PM	Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors (Business Wire) +5.85% +6.09%
Mar-12-25 04:05PM	Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum (Business Wire) -5.56%
Mar-06-25 04:05PM	Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones (Business Wire) +5.57% +5.12%
Mar-04-25 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 (Business Wire) -5.16%
Mar-03-25 04:05PM	Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference (Business Wire) -6.39%
Jan-08-25 04:05PM	Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) (Business Wire)
Jan-06-25 08:00AM	RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors (GlobeNewswire)
Dec-16-24 04:05PM	Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 (Business Wire)
Nov-25-24 08:05AM	Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference (Business Wire) +9.01%
Nov-18-24 08:05AM	Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain (Business Wire) -8.02%
Nov-13-24 04:05PM	Contineum Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Nov-06-24 04:05PM	Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) +7.60%
Aug-28-24 04:05PM	Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences (Business Wire) -7.00%
Aug-13-24 04:05PM	Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -6.06% +6.21%
Jul-31-24 04:05PM	Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis (Business Wire) -5.33%
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-04-24 04:05PM	Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference (Business Wire)
Jun-03-24 04:05PM	Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary (Business Wire)
May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

MSMr. Carmine N. Stengone MBA

Chief Financial OfficerMr. Peter T. Slover CPA

M.Sc.Dr. Timothy R. Watkins M.D.

Senior Manager of AccountingMs. Morgan Paulsen

Chief Science OfficerDr. Daniel S. Lorrain Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lorrain Daniel S.	Chief Scientific Officer	Jun 01 '26	Sale	13.16	4,170	54,862	139,372	Jun 01 06:08 PM
DANIEL LORRAIN	Officer	Jun 01 '26	Proposed Sale	13.49	4,170	56,253		Jun 01 04:19 PM
Lorrain Daniel S.	Chief Scientific Officer	May 01 '26	Sale	13.12	4,170	54,694	143,542	May 01 05:42 PM
DANIEL LORRAIN	Officer	May 01 '26	Proposed Sale	12.82	4,170	53,459		May 01 04:47 PM
Lorrain Daniel S.	Chief Scientific Officer	Apr 06 '26	Sale	13.43	4,170	56,014	147,712	Apr 06 05:43 PM
DANIEL LORRAIN	Officer	Apr 06 '26	Proposed Sale	13.44	914	12,284		Apr 06 04:33 PM
Lorrain Daniel S.	Chief Scientific Officer	Mar 02 '26	Sale	15.01	4,170	62,585	151,882	Mar 02 06:30 PM
Watkins Tim	CMO & Head of Development	Mar 02 '26	Option Exercise	4.50	3,611	16,250	3,611	Mar 02 06:28 PM
Watkins Tim	CMO & Head of Development	Mar 02 '26	Sale	15.02	3,611	54,220	0	Mar 02 06:28 PM
Stengone Carmine N.	CEO and President	Feb 24 '26	Option Exercise	1.26	4,400	5,544	19,354	Feb 26 04:40 PM
Stengone Carmine N.	CEO and President	Feb 25 '26	Option Exercise	1.26	2,700	3,402	17,654	Feb 26 04:40 PM
Stengone Carmine N.	CEO and President	Feb 24 '26	Sale	16.02	4,400	70,486	14,954	Feb 26 04:40 PM
Stengone Carmine N.	CEO and President	Feb 25 '26	Sale	16.02	2,700	43,242	14,954	Feb 26 04:40 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 24 '26	Option Exercise	1.01	4,300	4,343	160,352	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 25 '26	Option Exercise	1.01	3,824	3,862	159,876	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 24 '26	Sale	16.03	4,300	68,936	156,052	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 25 '26	Sale	16.01	3,824	61,228	156,052	Feb 26 04:39 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 19 '26	Option Exercise	1.01	100	101	156,152	Feb 20 04:05 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 19 '26	Sale	16.00	100	1,600	156,052	Feb 20 04:05 PM
Stengone Carmine N.	CEO and President	Feb 11 '26	Option Exercise	1.26	400	504	15,354	Feb 13 04:27 PM
Stengone Carmine N.	CEO and President	Feb 11 '26	Sale	16.00	400	6,400	14,954	Feb 13 04:27 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 11 '26	Option Exercise	1.01	400	404	156,452	Feb 13 04:26 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 11 '26	Sale	16.00	400	6,400	156,052	Feb 13 04:26 PM
DANIEL LORRAIN	Officer	Feb 11 '26	Proposed Sale	15.75	16,050	252,788		Feb 11 04:29 PM
CARMINE STENGONE	Director	Feb 11 '26	Proposed Sale	15.75	7,500	118,125		Feb 11 04:29 PM
Lorrain Daniel S.	Chief Scientific Officer	Feb 03 '26	Sale	14.94	4,170	62,305	156,052	Feb 05 04:24 PM
DANIEL LORRAIN	Officer	Feb 03 '26	Proposed Sale	14.38	4,170	59,965		Feb 03 04:32 PM
Watkins Tim	CMO & Head of Development	Jan 28 '26	Option Exercise	4.50	3,611	16,250	3,611	Jan 30 04:52 PM
Watkins Tim	CMO & Head of Development	Jan 28 '26	Sale	14.18	3,611	51,188	0	Jan 30 04:52 PM
Lorrain Daniel S.	Chief Scientific Officer	Jan 05 '26	Sale	10.44	4,170	43,543	160,222	Jan 06 04:16 PM
DANIEL LORRAIN	Officer	Jan 05 '26	Proposed Sale	11.39	4,170	47,496		Jan 05 04:42 PM
Watkins Tim	CMO & Head of Development	Dec 29 '25	Option Exercise	4.50	3,611	16,250	3,611	Dec 30 04:12 PM
Watkins Tim	CMO & Head of Development	Dec 29 '25	Sale	12.06	3,611	43,558	0	Dec 30 04:12 PM
Lorrain Daniel S.	Chief Scientific Officer	Dec 23 '25	Sale	12.23	4,170	51,009	164,392	Dec 30 04:10 PM
TIMOTHY WATKINS	Officer	Dec 29 '25	Proposed Sale	12.41	10,833	134,438		Dec 29 04:25 PM
DANIEL LORRAIN	Officer	Dec 23 '25	Proposed Sale	12.26	4,170	51,124		Dec 23 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc

Upgrade your Finviz experience